OR WAIT null SECS
October 06, 2026
Video
Chen discusses his experience with aortic and cardiac surgery, as well as ongoing research into ways to optimize and improve care.
October 02, 2026
Article
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
September 28, 2026
Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.
Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.
September 07, 2026
Rahul Aggarwal, MD, MBA, shares the results of his retrospective cohort study investigating the residual risk of heart failure after patients with prior MI.
August 29, 2026
POET-II found tailored antibiotics cut treatment duration by a third in left-sided infective endocarditis without compromising safety, per ESC 2026 data.
Philippe Gabriel Steg, MD, discusses the full results of the terminated trial, reflecting on their impact on the ongoing LIBREXIA-AF and LIBREXIA-Stroke trials.
August 18, 2026
Philippe Généreux, MD, discusses a secondary analysis of EARLY TAVR examining patients excluded from the trial for positive treadmill stress tests.
August 07, 2026
The phase 3 trial of evolocumab showed cardioprotective effects in patients without prior MI or stroke, regardless of qualifying atherosclerosis or background therapy.
August 01, 2026
July saw some of the biggest FDA approvals so far in 2026 – catch up on what you might have missed!